Researchers built a version of a brain-signalling peptide that stays switched off in the dark and turns on when light hits it, injected it into a pinhead-sized region of the mouse hypothalamus, and used a pulse of light to trigger a single burst of luteinizing hormone, the signal that sets off ovulation.
The tool is called azo-senktide, and the work appeared in the Journal of Neuroendocrinology ↗. It is a light-controlled copy of senktide, a lab-made molecule that imitates a natural brain peptide called neurokinin B and switches on a receptor named TacR3. That receptor sits on a small knot of cells in the arcuate nucleus, deep in the hypothalamus, the kisspeptin ↗ neurons. These neurons are the clock for reproduction. They fire in rhythmic bursts, and each burst tells the brain to release gonadotropin-releasing hormone, which in turn orders the pituitary gland to send out luteinizing hormone, or LH. The pattern of those pulses, not just their presence, is what keeps the reproductive system running.
The reason to bother making a light-switch is timing. A normal injected drug floods the receptor and stays there until the body clears it, so it cannot ask what happens if the receptor is switched on for a second, or a minute, or in a fast rhythm. Azo-senktide carries a molecular hinge that folds one way in the dark, an inactive shape the chemists call trans, and folds the other way under light into a more potent shape called cis. The flip is reversible, so the same molecule can be turned on and off again and again with light instead of chemistry.
The team climbed a ladder of models. In human HEK293T cells engineered to carry TacR3, light raised the receptor's calcium signalling. In slices of mouse hypothalamus kept alive in a dish, a flash of light made the kisspeptin neurons fire faster, through the same TacR3-to-TRPC5 channel route the field already suspected. Then came the live animal. Freely moving mice were fitted with a hair-thin optofluidic probe that delivers both the peptide and the light. Switching the peptide on inside the arcuate nucleus produced a clean, time-locked pulse of LH in the blood.
The sharpest result is what did not work. A pulse of LH appeared only at an intermediate dose. A smaller dose did nothing, and a larger one did nothing either. The receptor is not a simple on-switch that cares only whether an agonist is present. It responds to how much and how fast it is activated. That non-linear, Goldilocks response is the study's real payoff, because it may explain a long-standing frustration in this field: the same drugs often behave differently in a dish than in a living animal. If the circuit reads activation dynamics rather than mere presence, then the dose and the timing of a chemical experiment can flip the result. A light-gated peptide is one of the few ways to pin that down.
The limits are the usual ones for a tool like this. Everything here is in mice, and the peptide reaches its target through an implanted probe that pipes both drug and light straight into the brain, a laboratory manoeuvre, not a route any patient would take. Senktide itself is a research agonist, not a medicine, and azo-senktide is a probe built to ask mechanistic questions, not a fertility treatment. The findings come from a single group and a single paper. What the work buys is not a therapy but a cleaner way to interrogate the pulse generator that sits at the top of the reproductive axis.
On peptidemodel, this circuit maps onto two hosted targets. The kisspeptin neurons signal through the KISS1 receptor ↗, and the pulses they set off act downstream on the GnRH receptor ↗ that governs pituitary output. Kisspeptin is already used as a research probe for human fertility. Azo-senktide reaches one step further up the same chain, at the neurokinin B input, with control measured in seconds rather than hours. Whether that precision ever informs how the real drugs are dosed is an open question. It is exactly the kind of question the tool was built to ask.